» Articles » PMID: 36761748

Progress in the Cryoablation and Cryoimmunotherapy for Tumor

Overview
Journal Front Immunol
Date 2023 Feb 10
PMID 36761748
Authors
Affiliations
Soon will be listed here.
Abstract

With the rapid advancement of imaging equipment and minimally invasive technology, cryoablation technology is being used more frequently in minimally invasive treatment of tumors, primarily for patients with early tumors who voluntarily consent to ablation as well as those with advanced tumors that cannot be surgically removed or cannot be tolerated. Cryoablation is more effective and secure for target lesions than other thermal ablation methods like microwave and radiofrequency ablation (RFA). The study also discovered that cryoablation, in addition to causing tumor tissue necrosis and apoptosis, can facilitate the release of tumor-derived autoantigens into the bloodstream and activate the host immune system to elicit beneficial anti-tumor immunological responses against primary. This may result in regression of the primary tumor and distant metastasis. The additional effect called " Accompanying effects ". It is the basis of combined ablation and immunotherapy for tumor. At present, there is a lot of research on the mechanism of immune response induced by cryoablation. Trying to solve the question: how positively induce immune response. In this review, we focus on: 1. the immune effects induced by cryoablation. 2. the effect and mechanism of tumor immunotherapy combined with cryoablation. 3.The clinical research of this combination therapy in the treatment of tumors.

Citing Articles

Molecular MRI of T-cell immune response to cryoablation in immunologically hot . cold hepatocellular carcinoma.

Santana J, Shewarega A, Nam D, Duncan J, Madoff D, Hyder F JHEP Rep. 2025; 7(3):101294.

PMID: 40028344 PMC: 11870164. DOI: 10.1016/j.jhepr.2024.101294.


Precision oncology: The role of minimally-invasive ablation therapy in the management of solid organ tumors.

Fazlollahi F, Makary M World J Radiol. 2025; 17(1):98618.

PMID: 39876886 PMC: 11755905. DOI: 10.4329/wjr.v17.i1.98618.


Application of cryoablation in animal models of bladder and muscle-invasive bladder cancer: a narrative review of current status and future perspectives.

Wang Y, Li X Quant Imaging Med Surg. 2024; 14(12):9653-9666.

PMID: 39698593 PMC: 11652053. DOI: 10.21037/qims-24-1174.


Pulsed electric field ablation as a candidate to enhance the anti-tumor immune response to immune checkpoint inhibitors.

Arciga B, Walters D, Kimchi E, Staveley-OCarroll K, Li G, Teixeiro E Cancer Lett. 2024; 609:217361.

PMID: 39608443 PMC: 11625606. DOI: 10.1016/j.canlet.2024.217361.


Percutaneous cryoablation in soft tissue tumor management: an educational review.

Bodard S, Geevarghese R, Razakamanantsoa L, Frandon J, Petre E, Marcelin C Insights Imaging. 2024; 15(1):278.

PMID: 39556172 PMC: 11573955. DOI: 10.1186/s13244-024-01822-5.


References
1.
Liu X, Zhang W, Xu Y, Xu X, Jiang Q, Ruan J . Targeting PI3Kγ/AKT Pathway Remodels LC3-Associated Phagocytosis Induced Immunosuppression After Radiofrequency Ablation. Adv Sci (Weinh). 2022; 9(7):e2102182. PMC: 8895133. DOI: 10.1002/advs.202102182. View

2.
Gaitanis G, Bassukas I . Immunocryosurgery for non-superficial basal cell carcinomas ≤ 20 mm in maximal diameter: Five-year follow-up. J Geriatr Oncol. 2018; 10(3):475-478. DOI: 10.1016/j.jgo.2018.08.012. View

3.
BLACKWOOD C, Cooper I . Response of experimental tumor systems to cryosurgery. Cryobiology. 1972; 9(6):508-15. DOI: 10.1016/0011-2240(72)90172-1. View

4.
Benzon B, Glavaris S, Simons B, Hughes R, Ghabili K, Mullane P . Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer Prostatic Dis. 2018; 21(1):126-136. PMC: 5990963. DOI: 10.1038/s41391-018-0035-z. View

5.
Domingo-Musibay E, Heun J, Nevala W, Callstrom M, Atwell T, Galanis E . Endogenous Heat-Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma. Oncologist. 2017; 22(9):1026-e93. PMC: 5599201. DOI: 10.1634/theoncologist.2017-0060. View